INOVIO to Present at Upcoming Scientific and Investor Conferences
INOVIO, a biotechnology company developing DNA medicines, has announced its participation in several major scientific and investor conferences in May 2025. The company will present at the Citizens JMP Life Sciences Conference in New York through a fireside chat on May 8.
Notably, INOVIO will showcase new data about their lead candidate INO-3107 at multiple venues. Key presentations include:
- European Laryngological Society Annual Congress: Results showing 81% surgery reduction in adults with recurrent respiratory papillomatosis
- American Society of Gene and Cell Therapy: Treatment outcomes for recurrent respiratory papillomatosis
- American Broncho-Esophagological Association: Long-term clinical effects of INO-3107 in treating HPV 6 & 11-caused respiratory papillomatosis
Abstracts will be available on INOVIO's website after presentations, with the JMP conference webcast replay accessible for 90 days.
INOVIO, un'azienda biotecnologica specializzata nello sviluppo di farmaci a base di DNA, ha annunciato la sua partecipazione a importanti conferenze scientifiche e per investitori nel maggio 2025. L'azienda presenter脿 al Citizens JMP Life Sciences Conference di New York con una chiacchierata informale l'8 maggio.
INOVIO presenter脿 nuovi dati sul suo candidato principale INO-3107 in diverse sedi. Le presentazioni principali includono:
- Congresso annuale della European Laryngological Society: risultati che mostrano una riduzione dell'81% degli interventi chirurgici negli adulti affetti da papillomatosi respiratoria ricorrente
- American Society of Gene and Cell Therapy: risultati del trattamento per la papillomatosi respiratoria ricorrente
- American Broncho-Esophagological Association: effetti clinici a lungo termine di INO-3107 nel trattamento della papillomatosi respiratoria causata dai ceppi HPV 6 e 11
Gli abstract saranno disponibili sul sito web di INOVIO dopo le presentazioni, mentre la replica in webcast della conferenza JMP sar脿 accessibile per 90 giorni.
INOVIO, una empresa biotecnol贸gica que desarrolla medicamentos de ADN, ha anunciado su participaci贸n en varias conferencias cient铆ficas y de inversores importantes en mayo de 2025. La compa帽铆a presentar谩 en la Citizens JMP Life Sciences Conference en Nueva York mediante una charla informal el 8 de mayo.
INOVIO mostrar谩 nuevos datos sobre su candidato principal INO-3107 en m煤ltiples eventos. Las presentaciones clave incluyen:
- Congreso anual de la European Laryngological Society: resultados que muestran una reducci贸n del 81% en cirug铆as en adultos con papilomatosis respiratoria recurrente
- American Society of Gene and Cell Therapy: resultados del tratamiento para papilomatosis respiratoria recurrente
- American Broncho-Esophagological Association: efectos cl铆nicos a largo plazo de INO-3107 en el tratamiento de la papilomatosis respiratoria causada por HPV 6 y 11
Los res煤menes estar谩n disponibles en el sitio web de INOVIO despu茅s de las presentaciones, y la repetici贸n en webcast de la conferencia JMP estar谩 accesible durante 90 d铆as.
INOVIO電� DNA 鞚橃暯頀堨潉 臧滊皽頃橂姅 靸濍獏瓿淀暀 旮办梾鞙茧, 2025雲� 5鞗旍棎 鞐措Μ電� 欤检殧 瓿柬暀 氚� 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 5鞗� 8鞚� 雺挫殨鞐愳劀 臧滌禍霅橂姅 Citizens JMP Life Sciences Conference鞐愳劀 韺岇澊鞏挫偓鞚措摐 毂勴寘 順曥嫕鞙茧 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
韸鬼瀳 INOVIO電� 欤茧牓 頉勲炒氍检 INO-3107鞐� 雽�頃� 靸堧鞖� 雿办澊韯半ゼ 鞐煬 頄夓偓鞐愳劀 靹犽炒鞛呺媹雼�. 欤检殧 氚滍憸電� 雼れ潓瓿� 臧欖姷雼堧嫟:
- 鞙犽熃 頉勲憪頃欗殞 鞐半 齑濏殞: 鞛皽靹� 順疙潯旮� 鞙犽憪膦呾 靹膘澑 頇橃瀽鞐愳劀 靾橃垹 81% 臧愳唽 瓴瓣臣
- 氙戈淡 鞙犾爠鞛� 氚� 靹疙彫 旃橂頃欗殞: 鞛皽靹� 順疙潯旮� 鞙犽憪膦呾 旃橂 瓴瓣臣
- 氙戈淡 旮瓣磤歆�-鞁濍弰頃欗殞: HPV 6 氚� 11順曥棎 鞚橅暅 順疙潯旮� 鞙犽憪膦呾 旃橂鞐愳劀 INO-3107鞚� 鞛リ赴 鞛勳儊 須臣
氚滍憸 頉� INOVIO 鞗轨偓鞚错姼鞐愳劀 齑堧鞚� 頇曥澑頃� 靾� 鞛堨溂氅�, JMP 旎嵓霟办姢 鞗轨簮鞀ろ姼 鞛癌靻§潃 90鞚缄皠 鞁滌箔 臧�電ロ暕雼堧嫟.
INOVIO, une entreprise de biotechnologie d茅veloppant des m茅dicaments 脿 base d'ADN, a annonc茅 sa participation 脿 plusieurs grandes conf茅rences scientifiques et investisseurs en mai 2025. La soci茅t茅 pr茅sentera lors de la Citizens JMP Life Sciences Conference 脿 New York, 脿 travers une discussion informelle le 8 mai.
INOVIO mettra en avant de nouvelles donn茅es concernant son candidat principal INO-3107 lors de plusieurs 茅v茅nements. Les pr茅sentations cl茅s comprennent :
- Congr猫s annuel de la European Laryngological Society : r茅sultats montrant une r茅duction de 81 % des interventions chirurgicales chez les adultes atteints de papillomatose respiratoire r茅cidivante
- American Society of Gene and Cell Therapy : r茅sultats du traitement de la papillomatose respiratoire r茅cidivante
- American Broncho-Esophagological Association : effets cliniques 脿 long terme d'INO-3107 dans le traitement de la papillomatose respiratoire caus茅e par les HPV 6 et 11
Les r茅sum茅s seront disponibles sur le site web d'INOVIO apr猫s les pr茅sentations, la rediffusion du webinaire de la conf茅rence JMP 茅tant accessible pendant 90 jours.
INOVIO, ein Biotechnologieunternehmen, das DNA-Medikamente entwickelt, hat seine Teilnahme an mehreren bedeutenden wissenschaftlichen und Investorenkonferenzen im Mai 2025 angek眉ndigt. Das Unternehmen wird am 8. Mai auf der Citizens JMP Life Sciences Conference in New York in einem Fireside-Chat pr盲sentieren.
Besonders hervorzuheben ist, dass INOVIO neue Daten zu ihrem f眉hrenden Kandidaten INO-3107 an mehreren Veranstaltungsorten vorstellen wird. Wichtige Pr盲sentationen umfassen:
- Jahreskongress der Europ盲ischen Laryngologischen Gesellschaft: Ergebnisse, die eine 81%ige Reduktion von Operationen bei Erwachsenen mit rezidivierender respiratorischer Papillomatose zeigen
- American Society of Gene and Cell Therapy: Behandlungsergebnisse bei rezidivierender respiratorischer Papillomatose
- American Broncho-Esophagological Association: Langfristige klinische Effekte von INO-3107 bei der Behandlung der durch HPV 6 & 11 verursachten respiratorischen Papillomatose
Abstracts werden nach den Pr盲sentationen auf der INOVIO-Website verf眉gbar sein, und die Webcast-Wiedergabe der JMP-Konferenz ist f眉r 90 Tage zug盲nglich.
- INO-3107 shows strong clinical efficacy with 81% surgery reduction in adults with recurrent respiratory papillomatosis
- Multiple scientific presentations at major medical conferences indicating strong clinical data pipeline
- Successful treatment outcomes reported regardless of papilloma microenvironment and molecular subtype, suggesting broad applicability
- None.
Citizens JMP Life Sciences Conference (NY)
Date: May 8
Time: 11:30am EDT
Format: Fireside Chat
(audio webcast available here: )
European Laryngological Society Annual Congress (
Date: May 9
Oral presentation: DNA immunotherapy, INO-3107, generates targeted immunologic response and results in surgery reduction for
American Society of Gene and Cell Therapy (
Date: May 13
Poster Abstract Session: Successful Treatment of Recurrent Respiratory Papillomatosis with INO-3107 is Irrespective of Papilloma Microenvironment and Molecular Subtype
ABEA at COSM (
Date: May 15
Oral Presentation: DNA Immunotherapy (INO-3107) Durability and Long-Term Clinical Effect in Treatment of Recurrent Respiratory Papillomatosis Caused by HPV 6 & 11
Available abstracts will be shared on INOVIO's website following presentations. An audio replay of the Citizens JMP webcast will be available for 90 days after the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit .
Contacts
Media: Jennie Willson, (267) 429-8567, [email protected]
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505,听[email protected]
听
View original content to download multimedia:
SOURCE INOVIO Pharmaceuticals, Inc.
FAQ
When will INOVIO (INO) present at the Citizens JMP Life Sciences Conference 2025?
What are the key findings of INOVIO's INO-3107 treatment for respiratory papillomatosis?
Which scientific conferences will INOVIO present at in May 2025?
What is INOVIO's INO-3107 long-term clinical data presentation schedule?
How effective is INOVIO's INO-3107 across different papilloma subtypes?
